• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Acadia Healthcare Company Inc.

    5/30/25 5:01:57 PM ET
    $ACHC
    Medical Specialities
    Health Care
    Get the next $ACHC alert in real time by email
    S-8 1 ef20049831_s8.htm S-8
    As filed with the Securities and Exchange Commission on May 30, 2025
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    ACADIA HEALTHCARE COMPANY, INC.
    (Exact name of registrant as specified in its charter)

    Delaware
    (State or other jurisdiction of incorporation or organization)
     
    45-2492228
    (I.R.S. Employer Identification No.)

    6100 Tower Circle, Suite 1000
    Franklin, Tennessee
    (Address of Principal Executive Offices)
     
     
    37067
    (Zip Code)
     
    Acadia Healthcare Company, Inc. Amended and Restated Incentive Compensation Plan
    (Full title of the plan)

    Brian P. Farley
    Executive Vice President, General Counsel and Secretary
    Acadia Healthcare Company, Inc.
    6100 Tower Circle, Suite 1000
    Franklin, Tennessee 37067
    Telephone: (615) 861-6000
    (Name, address and telephone number, including area code, of agent for service)

    Copy to:
    James H. Nixon III
    Holland & Knight LLP
    511 Union Street, Suite 2700
    Nashville, Tennessee 37219
    Telephone: (615) 244-6380

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer
    ☒  
    Accelerated filer
    ☐
    Non-accelerated filer
    ☐  
    Smaller reporting company
    ☐
         
    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE

    This registration statement (this “Registration Statement”) is being filed pursuant to General Instruction E to Form S-8 and relates to the registration of an additional 2,475,000 shares of common stock of Acadia Healthcare Company, Inc. (the “Registrant”) issuable pursuant to the Acadia Healthcare Company, Inc. Amended and Restated Incentive Compensation Plan (the “Incentive Plan”). The contents of the Registrant’s registration statements on Form S-8 previously filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2011 (Reg. No. 333-177990), July 30, 2013 (Reg. No. 333-190232), May 20, 2016 (Reg. No. 333-211505) and August 3, 2021 (Reg. No. 333-258420), including all exhibits filed therewith or incorporated therein by reference, are incorporated herein by reference and made a part hereof, except as the same may be modified by the information set forth herein.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of this Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents need not be filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.
    Incorporation of Documents by Reference.

    The SEC allows us to “incorporate by reference” information into this Registration Statement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The following documents, which have been filed by the Registrant with the SEC, are incorporated in this Registration Statement by reference:

    (a)       The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024;
     
    (b)       The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025;
     
    (c)       The Registrant’s Current Reports on Form 8-K filed with the SEC on February 28, 2025, March 10, 2025 and May 30, 2025 (other than information furnished pursuant to Item 2.02 or Item 7.01 of the Current Report on Form 8-K, unless expressly stated otherwise therein); and
     
    (d)       The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the SEC pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on October 31, 2011 (Reg. No. 001-35331), including any amendments or reports filed for the purpose of updating such descriptions.
     
    All reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement, but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.
     
    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
     

    Item 4.
    Description of Securities.
     
    Not applicable.
     
    Item 5.
    Interests of Named Experts and Counsel.
     
    Not applicable.
     
    Item 6.
    Indemnification of Directors and Officers.
     
    The Registrant is incorporated under the laws of the State of Delaware. Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”) allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s amended and restated certificate of incorporation provides for this limitation of liability.
     
    Section 145 of the DGCL (“Section 145”) provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, were or are threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or director has actually and reasonably incurred.
     
    Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.
     
    The Registrant’s amended and restated bylaws provide that the Registrant must indemnify its directors and officers to the fullest extent authorized by the DGCL and must also pay expenses incurred in defending any such proceeding in advance of its final disposition; provided, that if and to the extent required by the DGCL, the advancement of expenses shall only be made upon delivery of an undertaking, by or on behalf of an indemnified person, to repay all amounts so advanced if it should be determined ultimately that such person is not entitled to be indemnified.
     
    The Registrant entered into indemnification agreements with each of its directors and executive officers. These agreements require the Registrant to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to the Registrant, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.
     
    The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of the Registrant’s certificate of incorporation or bylaws, agreement, vote of stockholders or disinterested directors or otherwise.
     

    The Registrant maintains standard policies of insurance that provide coverage (1) to its directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act and (2) to the Registrant with respect to indemnification payments that it may make to such directors and officers.
     
    Item 8.
    Exhibits.
     
    Exhibit
    Number
     
    Description
         
    4.1
     
    Amended and Restated Certificate of Incorporation of Acadia Healthcare Company, Inc. (the “Company”), as filed on October 28, 2011 with the Secretary of State of the State of Delaware, as amended by the Certificate of Amendments filed on May 25, 2017 and May 23, 2024. (a)
         
    4.2
     
    Amended and Restated Bylaws of the Company, as amended May 25, 2017. (b)
         
    4.3
     
    Specimen of the Company’s Common Stock Certificate. (c)
         
    4.4
     
    Amended and Restated Stockholders Agreement, dated as of October 29, 2014, by and among the Company and each of the stockholders named therein. (d)
         
    4.5
     
    Third Amended and Restated Registration Rights Agreement dated as of December 31, 2015, by and among the Company and each of the parties named therein. (e)
         
    4.6
     
    Joinder, dated February 16, 2016, to the Third Amended and Restated Registration Rights Agreement dated as of December 31, 2015, by and among the Company and each of the parties named therein. (f)
         
    5.1*
     
    Opinion of Holland & Knight LLP, with respect to the legality of the shares of common stock being registered hereby.
         
    23.1*
     
    Consent of Ernst & Young LLP, an independent registered public accounting firm, with respect to the audited financials of the Company.
         
    23.2
     
    Consent of Holland & Knight LLP (included in Exhibit 5.1).
         
    24
     
    Power of Attorney of certain officers and directors of the Company to file future amendments (set forth on the signature page of this Registration Statement).
         
    99.1
     
    Acadia Healthcare Company, Inc. Amended and Restated Incentive Compensation Plan, effective May 18, 2023. (g)
         
    99.2
     
    Amendment, effective May 29, 2025, to the Acadia Healthcare Company, Inc. Incentive Compensation Plan. (h)
         
    107*
     
    Filing Fee Table.


    *
    Filed herewith.
    (a)
    Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed May 24, 2024 (File No. 001-35331).
    (b)
    Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed May 25, 2017 (File No. 001-35331).
    (c)
    Incorporated by reference to exhibits filed with the Company’s registration statement on Form S-1, as amended (File No. 333-175523), originally filed with the SEC on November 23, 2011.
    (d)
    Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed October 30, 2014 (File No. 001-35331).
    (e)
    Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed January 4, 2016 (File No. 001-35331).
    (f)
    Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed February 16, 2016 (File No. 001-35331).
    (g)
    Incorporated by reference to Appendix B to the Company’s Definitive Proxy Statement filed with the SEC on April 10, 2025 (File No. 001-35331).
    (h)
    Incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement filed with the SEC on April 10, 2025 (File No. 001-35331).


    Item 9.
    Undertakings.
     
    (a)
    The undersigned registrant hereby undertakes:
     
    (1)          To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
     
    (i)          To include any prospectus required by Section 10(a)(3) of the Securities Act;
     
    (ii)         To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement;
     
    (iii)        To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
     
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
     
    (2)          That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (3)          To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
     
    (b)          The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (c)          Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Franklin of Tennessee, on May 30, 2025.
     
     
    ACADIA HEALTHCARE COMPANY, INC.
         
     
    By:
    /s/ Christopher H. Hunter
       
    Name: Christopher H. Hunter
       
    Title: Chief Executive Officer and Director

    POWER OF ATTORNEY
     
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brian P. Farley and Heather Dixon his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
     
    Signature
     
    Title
     
    Date
             
    /s/ Christopher H. Hunter
     
    Chief Executive Officer and Director
     
    May 30, 2025
    Christopher H. Hunter
     
    (Principal Executive Officer)
       
             
    /s/ Heather Dixon
     
    Chief Financial Officer
     
    May 30, 2025
    Heather Dixon
     
    (Principal Financial Officer and Principal Accounting Officer)
       
             
    /s/ Reeve B. Waud
     
    Chairman of the Board
     
    May 30, 2025
    Reeve B. Waud
           
             
    /s/ Jason R. Bernhard
     
    Director
     
    May 30, 2025
    Jason R. Bernhard
           
             
    /s/ E. Perot Bissell
     
    Director
     
    May 30, 2025
    E. Perot Bissell
           
             
    /s/ Michel J. Fucci
     
    Director
     
    May 30, 2025
    Michel J. Fucci
           
             
    /s/ Vicky B. Gregg
     
    Director
     
    May 30, 2025
    Vicky B. Gregg
           
             
    /s/ William F. Grieco
     
    Director
     
    May 30, 2025
    William F. Grieco
           
             
    /s/ Patrice A. Harris
     
    Director
     
    May 30, 2025
    Patrice A. Harris
           
             
    /s/ R. David Kelly
     
    Director
     
    May 30, 2025
    R. David Kelly
           
             
    /s/ Wade D. Miquelon
     
    Director
     
    May 30, 2025
    Wade D. Miquelon
           



    Get the next $ACHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHC

    DatePrice TargetRatingAnalyst
    1/22/2026$15.00Buy → Hold
    Jefferies
    12/3/2025$14.00Outperform → Market Perform
    Leerink Partners
    12/3/2025$13.00Neutral → Underperform
    BofA Securities
    9/10/2025$25.00Buy → Neutral
    BofA Securities
    8/14/2025$26.00Strong Buy → Outperform
    Raymond James
    2/28/2025$43.00 → $35.00Overweight → Equal Weight
    Barclays
    1/7/2025$70.00Sector Weight → Overweight
    KeyBanc Capital Markets
    12/12/2024$45.00 → $75.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $ACHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, GC and Secretary Farley Brian covered exercise/tax liability with 1,915 shares, decreasing direct ownership by 3% to 69,165 units (SEC Form 4)

    4 - Acadia Healthcare Company, Inc. (0001520697) (Issuer)

    2/27/26 5:01:02 PM ET
    $ACHC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Chief Executive Officer Osteen Debra K

    4 - Acadia Healthcare Company, Inc. (0001520697) (Issuer)

    1/21/26 4:34:50 PM ET
    $ACHC
    Medical Specialities
    Health Care

    New insider Osteen Debra K claimed ownership of 3,765 shares (SEC Form 3)

    3 - Acadia Healthcare Company, Inc. (0001520697) (Issuer)

    1/21/26 4:30:29 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acadia Healthcare downgraded by Jefferies with a new price target

    Jefferies downgraded Acadia Healthcare from Buy to Hold and set a new price target of $15.00

    1/22/26 8:24:52 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Acadia Healthcare from Outperform to Market Perform and set a new price target of $14.00

    12/3/25 8:27:09 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare downgraded by BofA Securities with a new price target

    BofA Securities downgraded Acadia Healthcare from Neutral to Underperform and set a new price target of $13.00

    12/3/25 8:27:09 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    SEC Filings

    View All

    Acadia Healthcare Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Acadia Healthcare Company, Inc. (0001520697) (Filer)

    2/25/26 7:08:15 AM ET
    $ACHC
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Acadia Healthcare Company Inc.

    SCHEDULE 13G - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    2/12/26 10:03:57 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Acadia Healthcare Company Inc.

    SCHEDULE 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    2/10/26 11:23:20 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acadia Healthcare Announces Fourth Quarter and 2025 Results

    Company Provides First Quarter and Full Year 2026 Guidance Debbie Osteen Joins Acadia as Chief Executive Officer Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Results Revenue totaled $821.5 million, a 6.1% increase compared with the fourth quarter of 2024, supporting full-year revenue results above the Company's previously issued guidance range Same facility revenue increased 4.4% compared with the fourth quarter of 2024, including an increase in patient days of 3.1% and an increase in revenue per patient day of 1.3% Net loss attributable

    2/25/26 7:00:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare to Participate in March Investor Conferences

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that the Company will participate in three investor conferences in March. On Monday, March 2, 2026, the Company will participate in the Raymond James & Associates' 47th Annual Institutional Investors Conference, being held March 1-4, 2026, in Orlando, Florida. The Company's presentation/fireside chat will begin at 11:35 a.m. Eastern Time/10:35 a.m. Central Time. On Monday, March 9, 2026, the Company will participate in the Leerink Partners 2026 Global Healthcare Conference, being held March 9-12, 2026, in Miami, Florida. The Company's presentation will begin at 3:40 p.m. Eastern Time/2:40 p.m. Central Time. On Tuesday, Marc

    2/20/26 11:00:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2025 Earnings Release

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that it will release its fourth quarter and year-end 2025 results on Wednesday, February 25, 2026, before the market opens. Acadia will also conduct a conference call with institutional investors and analysts on Wednesday, February 25, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website. The webcast of the conference call will be available for 30 days. About Acadia Healthcare Acadia is a leading provider of behavioral healthcare services across the United States (the "U.S."). As of September 30, 2025, Acadia operated a network of

    2/4/26 10:00:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/14/24 1:28:32 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/12/24 9:50:14 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/8/24 10:52:39 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Financials

    Live finance-specific insights

    View All

    Acadia Healthcare Announces Fourth Quarter and 2025 Results

    Company Provides First Quarter and Full Year 2026 Guidance Debbie Osteen Joins Acadia as Chief Executive Officer Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Results Revenue totaled $821.5 million, a 6.1% increase compared with the fourth quarter of 2024, supporting full-year revenue results above the Company's previously issued guidance range Same facility revenue increased 4.4% compared with the fourth quarter of 2024, including an increase in patient days of 3.1% and an increase in revenue per patient day of 1.3% Net loss attributable

    2/25/26 7:00:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2025 Earnings Release

    Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that it will release its fourth quarter and year-end 2025 results on Wednesday, February 25, 2026, before the market opens. Acadia will also conduct a conference call with institutional investors and analysts on Wednesday, February 25, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website. The webcast of the conference call will be available for 30 days. About Acadia Healthcare Acadia is a leading provider of behavioral healthcare services across the United States (the "U.S."). As of September 30, 2025, Acadia operated a network of

    2/4/26 10:00:00 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Reports Third Quarter 2025 Results

    Third Quarter Revenue of $851.6 Million Increased 4.4% Year-Over-Year Lowering Full-Year Outlook Acadia Taking Decisive Actions to Optimize Portfolio in Order to Reduce Capital Expenditures and Increase Free Cash Flow Generation Referral Initiatives Drive Accelerating Admissions Growth Todd Young joined as CFO on October 27; Announces departure of COO Dr. Nasser Khan Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Results Revenue totaled $851.6 million, an increase of 4.4% over the third quarter of 2024 Same facility revenue increased 3.7% compared with th

    11/5/25 4:05:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    Leadership Updates

    Live Leadership Updates

    View All

    Acadia Healthcare Appoints Debbie Osteen as Chief Executive Officer

    Reaffirms Full-Year 2025 Guidance Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced that Debra K. Osteen, former Board member and former Chief Executive Officer of Acadia, has been appointed CEO, effective immediately. Osteen, who has also been appointed as a member of the Board, succeeds Chris Hunter, who is departing the Company and its Board of Directors. Reeve Waud, Chairman of Acadia's Board of Directors, said, "As Acadia continues to take decisive steps to optimize its growth investments and existing portfolio amidst ongoing macro headwinds facing many healthcare providers, the Board believes now is the right time to transition leadership. D

    1/20/26 8:00:00 AM ET
    $ACHC
    $UHS
    Medical Specialities
    Health Care
    Hospital/Nursing Management

    Acadia Healthcare Appoints Todd Young as Chief Financial Officer

    Young Brings 25 Years of Financial and Healthcare Industry Experience Acadia Healthcare Company, Inc. (NASDAQ:ACHC) ("Acadia" or the "Company") today announced the appointment of Todd Young as Chief Financial Officer, effective October 27, 2025. Tim Sides, who has been serving as the Company's interim CFO since August 2025, will resume his role as Senior Vice President, Operations Finance. Young brings to Acadia nearly a decade of executive-level finance experience at publicly traded healthcare companies. He most recently served as CFO at Elanco Animal Health ("Elanco") where he joined in 2018 as Elanco was separating from Eli Lilly and Company. Young developed a robust finance organiza

    10/7/25 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology